Gilead’s Cell Therapy Opportunity Tempts Maxim to Join the Bullish Camp

Maxim analyst Jason McCarthy has decided the bulls are right when it comes to the meaningful prospects glittering ahead for Gilead Sciences (NASDAQ:GILD) in the playing field of cell therapy- especially following its savvy Kite acquisition, strengthening the biotech giant’s upper hand. Now that McCarthy has come back from a management meeting in Beijing, China he is out making a new case for why now is the time to buy shares.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts